Novozymes Biopharma and Millipore Corporation have launched the first product from their alliance to supply animal-free cell culture supplements for bioprocessing.
Cellprime Rtransferrin AF is an animal-free alternative to serum-derived human or bovine transferrin for industrial cell culture and upstream biopharmaceutical applications.
Cellprime is a range of animal-free cell culture supplements that enable customers to utilise defined, animal-free supplements in their biopharmaceutical production processes.
The Rtransferrin AF is claimed to offer benefits over current plasma-derived alternatives, including facilitating effective iron uptake into cells for optimal cell culture, and is now commercially available in scalable manufacturing quantities.
Cellprime Rtransferrin AF is designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers.
It also improves the consistency of batch quality and productivity of industrial cell culture processes.
Manufactured in FDA-inspected facilities to CGMP standards, Cellprime Rtransferrin AF is suitable for both research and commercial-scale mammalian cell culture.
Samples of the animal-free supplement are available from Millipore.
This product will be manufactured by Novozymes Biopharma and sold exclusively through Millipore's sales organisation.
